Co-Founder & CEO Alison Liddy describes Relevium's program, which is designed to be an extended release prodrug. The initial clinical indication will be osteoarthritis of the knee.
Coverage brought to you by
Also look for unique social pages for BiotechTV U.
10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.
Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.
.png){kind=logo}